Nicholas Canaday
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicholas Canaday has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Munoz-Casabella
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota
5 shared publications - Arthur E. Warrington
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota
5 shared publications - Cecile Riviere-Cazaux
Department of Neurological Surgery, Mayo Clinic , Rochester, MN
5 shared publications - Chao Dai
Predicine, Inc., Hayward, California
5 shared publications - Cody L. Nesvick
Department of Neurological Surgery, Mayo Clinic , Rochester, Minnesota
5 shared publications - David M. Routman
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
5 shared publications
Latest Publications
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 2. Tissue vs. CSF NGS in patients 24, 78, and 79.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 2. Tissue vs. CSF NGS in patients 24, 78, and 79.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Table 3. Representativeness of Study Participants.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Table 3. Representativeness of Study Participants.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 1. List of 152 genes on PredicineCARE panel.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplemental Table 1. List of 152 genes on PredicineCARE panel.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Materials, including Figures/Figure legends S1-2 and note on Predicine CARE/CNB validation.
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials 1 from Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Supplementary Materials, including Figures/Figure legends S1-2 and note on Predicine CARE/CNB validation.
- Open Access
- 23 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (5) , 881-889
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
- 23 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (5) , 881-889
Open AccessLongitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.